Chia Tai Tianqing’s TQB2210 Approved for Advanced Malignant Tumor Study
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved...
Drug
Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving approval from the National...
Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...
AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China
UK-based pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has announced the official market launch of its...
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...
Joint Biosciences’ OVV-01 Receives FDA Fast Track Designation for Soft Tissue Sarcoma Trial
Shanghai-based Joint Biosciences Ltd., a developer of tumor combined immunotherapies, has announced receiving fast track...
Sino Biopharmaceutical’s Culmerciclib Shows Positive Results in Phase III Breast Cancer Trial
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has revealed positive results from the Phase III TQB3616-III-02...
Humanwell Healthcare Receives NMPA Approval for Caplyta Generic in Schizophrenia Trial
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced receiving clinical trial approval from...
China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement
China’s National Healthcare Security Administration (NHSA) has released its 2024 “Healthcare Security Development Statistical Bulletin.”...
SineuGene Therapeutics’ SNUG01 Receives FDA Clearance for ALS Clinical Study
Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced last week that...
GSK’s Nucala Accepted for EMA Review for COPD Treatment
UK-based GSK plc’s (LON: GSK, NYSE: GSK) application for expanding the use of its anti-interleukin-15...
Shanghai Ark Biopharmaceutical’s AK0901 Meets Phase III Endpoints in ADHD Trial
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study...
Suzhou Xueji Biotech’s XJ-MK-002 Gets FDA Orphan Drug Designation for CAMT
China-based cell therapy developer Suzhou Xueji Biotechnology Co., Ltd’s (HemaCell) XJ-MK-002, described as the world’s...
Beijing Sungen Biomedical’s SGC001 Receives FDA Fast Track Designation for AMI Treatment
China-based Beijing Sungen Biomedical Technology Co., Ltd, an antibody developer incubated by Hotgen Biotech Co.,...
AllianThera Biopharma Starts Global Phase I Trial for ATB102 in Inflammatory Bowel Diseases
Suzhou-based startup AllianThera Biopharma has announced the first patient dosing in a global Phase I...
Jiangsu Hengrui Pharmaceuticals’ Ivarmacitinib Receives NMPA Approval for Ankylosing Spondylitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving marketing approval from the National...
Kexing Biopharm Partners with BioMap on AI-Driven Macromolecular Drug Development
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap...
CStone Pharmaceuticals Files for EMA Approval of Sugemalimab for Unresectable Stage III NSCLC
China-based CStone Pharmaceuticals (HKG: 2616) has announced filing for another indication approval for its anti-programmed...
Clover Biopharmaceuticals Receives FDA Approval for SCB-1019 RSV Vaccine Trial
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced receiving clinical approval from the US Food...
AIM Vaccine’s mRNA-based Shingles Vaccine Receives FDA Approval for Clinical Study
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the US Food...